Search company, investor...
BioNTech company logo


Founded Year




Total Raised


Market Cap


Stock Price




About BioNTech

BioNTech (NASDAQ: BNTX) offers new immunotherapy solutions for cancer and other diseases. The Company focuses on the computational discovery and therapeutic drug platforms for developing biopharmaceuticals. It works with pharmaceutical collaborators, such as Genmab, Sanofi, Genentech, Genevant, Fosun Pharma, and Pfizer. The company was founded in 2008 and is based in Mainz, Germany.

Headquarters Location

An der Goldgrube 12

Mainz, 55131,



Missing: BioNTech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioNTech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing BioNTech

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BioNTech in 2 CB Insights research briefs, most recently on Apr 19, 2021.

Expert Collections containing BioNTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioNTech is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

BioNTech Patents

BioNTech has filed 210 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immune system, Immunology, Cytokines, Transcription factors


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immune system, Immunology, Cytokines, Transcription factors



Latest BioNTech News

Pfizer is preparing a new strike. Research a shingles vaccine

May 27, 2023

. A successful new collaboration between Pfizer and BioNTech is announced. And all for a vaccine that can change the fate of many patients. BioNTech and Pfizer first collaborated in the field of infectious diseases in 2018, when they teamed up to develop a messenger RNA-based influenza vaccine. But they gained notoriety only with their second successful collaboration, which brought the first messenger RNA-based COVID-19 vaccine to market and received emergency use approval in December 2020. You might also be interested in: How long does alcohol stay in the body after drinking… Pfizer is preparing a new strike. Pfizer and BioNTech aim to develop an improved vaccine for an infectious disease using messenger RNA-based serum technology, the site reports Bioprocessintl . Pfizer and BioNTech are developing a vaccine for shingles Now, the two companies have teamed up again to produce a vaccine for shingles (herpes zoster). What is shingles and how many people does it affect? Shingles is a chronic form of the varicella zoster virus (VZV), which affects about one in three people in the US during their lifetime. The infection can cause an extremely painful rash, and in rare conditions can lead to deafness, blindness, and even facial paralysis. You might also be interested in: These are the benefits of eating chicken… “The collaboration aims to develop a new mRNA-based vaccine against zoster, leveraging the expertise and resources of both companies,” said Ugur Sahin, CEO of BioNTech. “Adults age 50 and older, as well as vulnerable populations such as cancer patients, are at increased risk for shingles. Our goal is to develop an mRNA-based vaccine with a favorable safety profile and high efficacy that is at the same time more easily scalable to support global access,” he emphasized. You might also be interested in: Cardiologist: these are the foods most … How the research money will be divided Under the agreement, the two companies will share development costs, but BioNTech will receive an upfront payment of $225 million, plus another $75 million and an equity investment of $150 million. The German firm will also have the right to receive up to $200 million in future marketing and sales fees, and Pfizer will collect an upfront payment of $25 million from BioNTech for the use of its antigen sequences . You might also be interested in: The new population vaccination campaign in Italy… Pfizer and BioNTech want an improved vaccine Two vaccines have been approved so far to treat shingles, one from GlaxoSmithKline and one from Merck & Co. Zostavax. However, Pfizer and BioNTech say there is enough room in the market to develop an improved vaccine that has the potential to produce greater efficacy and better tolerability using mRNA technology The information presented in this website is informative and does not replace the medical diagnosis or the product leaflet. Any decision regarding your health should only be made after consulting your doctor.

BioNTech Frequently Asked Questions (FAQ)

  • When was BioNTech founded?

    BioNTech was founded in 2008.

  • Where is BioNTech's headquarters?

    BioNTech's headquarters is located at An der Goldgrube 12, Mainz.

  • What is BioNTech's latest funding round?

    BioNTech's latest funding round is PIPE.

  • How much did BioNTech raise?

    BioNTech raised a total of $771.5M.

  • Who are the investors of BioNTech?

    Investors of BioNTech include Temasek, Bill & Melinda Gates Foundation, Sanofi, Pfizer, Invus Group and 8 more.

  • Who are BioNTech's competitors?

    Competitors of BioNTech include Ethris and 1 more.

Compare BioNTech to Competitors

Recode Therapeutics Logo
Recode Therapeutics

ReCode Therapeutics is a genetic medicines company for mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. The company's lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. Recode Therapeutics was founded in 2015 and is based in Menlo Park, California.

HDT Bio Logo

HDT Bio is a biopharmaceutical company. It develops drugs for immunotherapy of cancers and infectious diseases. It provides ribonucleic-based vaccines and therapeutics for infectious disease and oncology. The company was founded in 2018 and is based in Seattle, Washington.

Ethris Logo

Ethris develops mRNA therapeutics with a focus on respiratory diseases and vaccines. Its RNA technology platform helps enable the discovery, design, and development of transcript therapies that assist in restoring missing functions in patients' cells and tissues. The company was founded in 2009 and is based in Planegg, Germany.

Moderna Therapeutics Logo
Moderna Therapeutics

Moderna Therapeutics (NASDAQ: MRNA) is a biotechnology company that is focused on drug discovery and drug development based on messenger RNA. It creates synthetic mRNA that can be injected into patients to help them create their own therapies. The company was founded in 2010 and is based in Cambridge, Massachusetts.

Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ: ARCT) is a global late-stage clinical messenger ribonucleic acid (RNA) medicines and vaccines company. It focuses on the discovery and development of therapeutic modalities to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment. It was founded in 2013 and is based in San Diego, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.